Subject(s)
Anti-Bacterial Agents/therapeutic use , Cross Infection/drug therapy , Gram-Negative Bacterial Infections/drug therapy , Minocycline/analogs & derivatives , Pneumonia, Bacterial/drug therapy , Stenotrophomonas maltophilia/drug effects , Aged , Carcinoma, Transitional Cell/complications , Cross Infection/complications , Cross Infection/physiopathology , Drug Resistance, Multiple , Emphysema/complications , Gram-Negative Bacterial Infections/complications , Gram-Negative Bacterial Infections/physiopathology , Humans , Lupus Erythematosus, Discoid/complications , Male , Minocycline/therapeutic use , Obesity/complications , Pneumonia, Bacterial/complications , Pneumonia, Bacterial/physiopathology , Pulmonary Disease, Chronic Obstructive/complications , Tigecycline , Urinary Bladder Neoplasms/complicationsABSTRACT
The efficacy and safety of once-daily beclomethasone dipropionate (BDP; 200 microg), in combination with the propellant hydrofluoroalkane-134a (HFA) was compared with that of budesonide turbuhaler (BUD-TH) 400 microg twice daily and fluticasone propionate inhaler (FP-IH) 250 microg twice daily in 40 patients with bronchial asthma or chronic obstructive pulmonary disease. All patients had used inhaled corticosteroids for at least 1 month. On randomization, 20 patients were switched to HFA-BDP and 20 patients remained on their existing BUD-TH or FP-IH treatment. After 8 weeks, HFA-BDP demonstrated a greater improvement in spirometric values, respiratory symptoms and beta2-agonist use. No significant local adverse effects were observed. Blood cortisol levels remained in the normal range in both groups. We conclude that HFA-BDP (200 microg once-daily) offered more benefit in terms of clinical and spirometry indices than BUD-TH (400 microg twice daily) or FP-IH (250 microg twice daily) in patients with moderate asthma and chronic obstructive pulmonary disease.
